UPDATE: Needham & Company Upgrades Chelsea Therapeutics (CHTP) to Buy
Tweet Send to a FriendGet Alerts CHTP Hot Sheet
Price: $2.29 -6.53%
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade CHTP Now!
(Updated - February 20, 2013 2:42 PM EST)
Needham & Company upgraded Chelsea Therapeutics (NASDAQ: CHTP) from Hold to Buy with a $4 price target following encouraging progress in its discussions with the FDA around regulatory path for Northera, which is under development for Neurogenic Orthostatic Hypotension (NOH).
"Although we believe Northera regulatory risk is still meaningful, the FDA appears willing to demonstrate greater flexibility in the review process. Given current low valuation ($75M EV), we believe the risk benefit profile for the stock is reasonably attractive. We are upgrading the stock to BUY (was HOLD) with a $4 target based on 25x our $0.26 2016 EPS estimate, discounted 25%."
For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.
Shares of Chelsea Therapeutics closed at $0.77 yesterday, with a 52 week range of $0.70-$4.40.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Needham & Company upgraded Chelsea Therapeutics (NASDAQ: CHTP) from Hold to Buy with a $4 price target following encouraging progress in its discussions with the FDA around regulatory path for Northera, which is under development for Neurogenic Orthostatic Hypotension (NOH).
"Although we believe Northera regulatory risk is still meaningful, the FDA appears willing to demonstrate greater flexibility in the review process. Given current low valuation ($75M EV), we believe the risk benefit profile for the stock is reasonably attractive. We are upgrading the stock to BUY (was HOLD) with a $4 target based on 25x our $0.26 2016 EPS estimate, discounted 25%."
For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.
Shares of Chelsea Therapeutics closed at $0.77 yesterday, with a 52 week range of $0.70-$4.40.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
- JPMorgan Upgrades People's United Financial (PBCT) to Overweight
- UPDATE: Raymond James Downgrades Gevo, Inc. (GEVO) to Market Perform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
